Great work! Will be interesting to see the real-world evidence of re-exposure in pts who had a CR1 and the duration of CR2. Also raising the question if allo transplant should be considered among patients r/r to CAR and in CR with a BsAbs.
Can’t wait for more data and real-world evidence !

I’m surprised to see the mPFS of R2 at 13.9 months, whereas it was 39 months in the AUGMENT trial. Looking forward to learning more!